HO ΗQ -NH-R<sup>1</sup> -NH  $H_3C$ ΗQ HŃ ΩН O: ŅΗ **(I)**  $CH_3$  $H_2N$ O: ΗQ -NH ρн ρн HO

wherein  $R^1$  is benzoyl substituted with isoxazolyl which has phenyl having lower alkoxy, or a salt thereof.

38. A compound of claim 3/1, wherein R<sup>1</sup> is

$$T_{i}\partial \mathcal{D}^{i}$$
 —CO— $N$ —O—(CH<sub>2</sub>)<sub>4</sub>CH<sub>3</sub>

3.39. A process for the preparation of a polypeptide compound of the formula (I):

Cont

-2-

250

ΗQ ΗQ -NH-R<sup>1</sup> H<sub>3</sub>C, ΗÓ ΗŃ ΩН **(**I) ΗŲ CH<sub>3</sub>  $H_2N$ O= HQ -NH ЭΗ ρн НО

wherein R<sup>1</sup> is benzoyl substituted with isoxazolyl which has phenyl having lower alkoxy, or a salt thereof, said process comprising:

1) reacting a compound of the formula (II):



QН HQ ΗŌ  $-NH_2$  $H_3C$ ΗQ ΗŃ ŊН ЙH (II)CH<sub>3</sub> O: HO -NH ДΗ ÒΗ HO

or its reactive derivative at the amino group or a salt thereof, with a compound of formula (III):

R<sup>1</sup>-OH (III)

or its reactive derivative at the carboxy group or a salt thereof, wherein R<sup>1</sup> is defined above, to give a compound of formula (I).

A pharmaceutical composition which comprises, as an active ingredient, a compound of claim 37, or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable carrier or excipient.

Con

C 354